{
  "resourceType" : "PlanDefinition",
  "id" : "IMMZD2DTMeaslesSupplementary",
  "meta" : {
    "profile" : ["http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-recommendationdefinition",
    "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableplandefinition",
    "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableplandefinition"]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: PlanDefinition </b><a name=\"IMMZD2DTMeaslesSupplementary\"> </a><a name=\"hcIMMZD2DTMeaslesSupplementary\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">ResourcePlanDefinition &quot;IMMZD2DTMeaslesSupplementary&quot; </p><p style=\"margin-bottom: 0px\">Profiles: <a href=\"https://build.fhir.org/ig/HL7/cqf-recommendations/StructureDefinition-cpg-recommendationdefinition.html\">CPG Recommendation Definition</a>, <a href=\"http://hl7.org/fhir/uv/crmi/STU1/StructureDefinition-crmi-shareableplandefinition.html\">CRMI Shareable PlanDefinition</a>, <a href=\"http://hl7.org/fhir/uv/crmi/STU1/StructureDefinition-crmi-publishableplandefinition.html\">CRMI Publishable PlanDefinition</a></p></div><p><b>CQF Knowledge capability</b>: computable</p><p><b>url</b>: <code>http://smart.who.int/immunizations-measles/PlanDefinition/IMMZD2DTMeaslesSupplementary</code></p><p><b>version</b>: 0.1.0</p><p><b>name</b>: IMMZD2DTMeaslesSupplementary</p><p><b>title</b>: IMMZ.D2.DT.Measles MCV Dose 0</p><p><b>type</b>: ECA Rule <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.5.0/CodeSystem-plan-definition-type.html\">PlanDefinitionType</a>#eca-rule)</span></p><p><b>status</b>: draft</p><p><b>experimental</b>: true</p><p><b>date</b>: 2024-06-06 23:41:54+0000</p><p><b>publisher</b>: WHO</p><p><b>contact</b>: WHO: <a href=\"http://who.int\">http://who.int</a></p><p><b>description</b>: If the child or patient has not been given a supplementary dose</p><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Citation</b></td></tr><tr><td style=\"display: none\">*</td><td>citation</td><td>WHO recommendations for routine immunization - summary tables (March 2023)</td></tr></table><p><b>library</b>: <a href=\"Library-IMMZD2DTMeaslesSupplementaryLogic.html\">IMMZD2DTMeaslesSupplementaryLogic</a></p><blockquote><p><b>action</b></p><p><b>title</b>: Immunize patient for Measles</p><blockquote><p><b>condition</b></p><p><b>kind</b>: applicability</p><h3>Expressions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Language</b></td><td><b>Expression</b></td></tr><tr><td style=\"display: none\">*</td><td>text/cql-identifier</td><td>Measles Routine Immunization Schedule Complete</td></tr></table></blockquote><blockquote><p><b>action</b></p><p><b>CPG Rationale Extension</b>: An additional dose of MCV should be administered to HIV-infected children receiving HAART following immune reconstitution. If CD4+ T lymphocyte counts are monitored, an additional dose of MCV should be administered when immune reconstitution has been achieved, e.g. when the CD4+ T lymphocyte count reaches 20–25%. Where CD4+ T lymphocyte monitoring is not available, children should receive an additional dose of MCV 6–12 months after initiation of HAART.&lt;br/&gt;As a general rule, live vaccines should be given either simultaneously or at intervals of 4 weeks. An exception to this rule is OPV, which can be given at any time before or after measles vaccination without interference in the response to either vaccine</p><p><b>title</b>: Consider supplementary dose</p><blockquote><p><b>condition</b></p></blockquote><blockquote><p><b>action</b></p></blockquote><blockquote><p><b>action</b></p></blockquote></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Supplementary Dose Administered</p><p><b>description</b>: Measles immunization schedule is complete. Measles supplementary dose was administered.</p><blockquote><p><b>condition</b></p></blockquote></blockquote></blockquote></div>"
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
    "valueCode" : "computable"
  }],
  "url" : "http://smart.who.int/immunizations-measles/PlanDefinition/IMMZD2DTMeaslesSupplementary",
  "version" : "0.1.0",
  "name" : "IMMZD2DTMeaslesSupplementary",
  "title" : "IMMZ.D2.DT.Measles MCV Dose 0",
  "type" : {
    "coding" : [{
      "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
      "code" : "eca-rule"
    }]
  },
  "status" : "draft",
  "experimental" : true,
  "date" : "2024-06-06T23:41:54+00:00",
  "publisher" : "WHO",
  "contact" : [{
    "name" : "WHO",
    "telecom" : [{
      "system" : "url",
      "value" : "http://who.int"
    }]
  }],
  "description" : "If the child or patient has not been given a supplementary dose",
  "relatedArtifact" : [{
    "type" : "citation",
    "citation" : "WHO recommendations for routine immunization - summary tables (March 2023)"
  }],
  "library" : ["http://smart.who.int/immunizations-measles/Library/IMMZD2DTMeaslesSupplementaryLogic"],
  "action" : [{
    "title" : "Immunize patient for Measles",
    "condition" : [{
      "kind" : "applicability",
      "expression" : {
        "language" : "text/cql-identifier",
        "expression" : "Measles Routine Immunization Schedule Complete"
      }
    }],
    "action" : [{
      "extension" : [{
        "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-rationale",
        "valueMarkdown" : "An additional dose of MCV should be administered to HIV-infected children receiving HAART following immune reconstitution. If CD4+ T lymphocyte counts are monitored, an additional dose of MCV should be administered when immune reconstitution has been achieved, e.g. when the CD4+ T lymphocyte count reaches 20–25%. Where CD4+ T lymphocyte monitoring is not available, children should receive an additional dose of MCV 6–12 months after initiation of HAART.<br/>As a general rule, live vaccines should be given either simultaneously or at intervals of 4 weeks. An exception to this rule is OPV, which can be given at any time before or after measles vaccination without interference in the response to either vaccine"
      }],
      "title" : "Consider supplementary dose",
      "condition" : [{
        "kind" : "applicability",
        "expression" : {
          "language" : "text/cql-identifier",
          "expression" : "No Supplementary Dose Administered"
        }
      }],
      "action" : [{
        "title" : "Last Live Vaccine Administered Within 4 Weeks",
        "description" : "Should not vaccinate client for measles supplementary dose as live vaccine was administered in the last 4 weeks. Check for any vaccines due, and inform the caregiver of when to come back for supplementary dose.",
        "condition" : [{
          "kind" : "applicability",
          "expression" : {
            "language" : "text/cql-identifier",
            "expression" : "Last Live Vaccine Administered Within 4 Weeks"
          }
        }]
      },
      {
        "title" : "Provide Measles Vaccine",
        "description" : "May vaccinate client for measles supplementary dose as supplementary dose was not administered, measles routine immunization schedule is complete and no live vaccine administered in the last 4 weeks. Check if one of the measles supplementary dose specific scenarios is applicable.",
        "condition" : [{
          "kind" : "applicability",
          "expression" : {
            "language" : "text/cql-identifier",
            "expression" : "Client Is Due For Supplementary Dose"
          }
        }],
        "definitionCanonical" : "http://smart.who.int/immunizations-measles/ActivityDefinition/IMMZD2DTMeaslesMR",
        "dynamicValue" : [{
          "path" : "dispenseRequest.validityPeriod.start",
          "expression" : {
            "description" : "Due date of the dose",
            "language" : "text/cql-identifier",
            "expression" : "MCV Supplementary Schedule Date"
          }
        },
        {
          "path" : "dispenseRequest.validityPeriod.end",
          "expression" : {
            "description" : "Expiration date for MCV dose",
            "language" : "text/cql-identifier",
            "expression" : "MCV Supplementary Expiration Date"
          }
        }]
      }]
    },
    {
      "title" : "Supplementary Dose Administered",
      "description" : "Measles immunization schedule is complete. Measles supplementary dose was administered.",
      "condition" : [{
        "kind" : "applicability",
        "expression" : {
          "language" : "text/cql-identifier",
          "expression" : "Supplementary Dose Administered"
        }
      }]
    }]
  }]
}